3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Injections
3
Cytarabine
3
pegylated granulocyte colony-stimulating factor
2
Decitabine
2
Daunorubicin
2
Cladribine
2
Biopsy
2
Azacitidine
2
venetoclax
1
ruxolitinib
1
fludarabine phosphate
1
fedratinib
1
enasidenib
1
Whole-Body Irradiation
1
Tacrolimus
1
Spinal Puncture
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Mycophenolic Acid
1
Mitoxantrone
1
Liposomes
1
Gemtuzumab
1
Cyclophosphamide
1
CPX-351
1
Bone Marrow Transplantation
1
2'-chloro-2'-deoxyadenosine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Monocytic, Acute
×
tipifarnib
×
90 days
×
Clear all
No trials found.